81 research outputs found
Switching to different generic medicines: A checklist for safety issues
ΠΠΎΠ½ΠΊΡΡΠ΅Π½ΡΠΈΡΡΠ° ΠΌΠ΅ΠΆΠ΄Ρ ΠΏΡΠ΅Π΄Π»Π°Π³Π°Π½ΠΈΡΠ΅ Π½Π° ΠΏΠ°Π·Π°ΡΠ° Π³Π΅Π½Π΅ΡΠΈΡΠ½ΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½ΠΈ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈ Π²ΠΎΠ΄ΠΈ Π΄ΠΎ ΠΏΠΎ-Π½ΠΈΡΠΊΠΈ ΡΠ΅Π½ΠΈ ΠΈ Π½Π°ΠΌΠ°Π»Π΅Π½ΠΈ ΡΠ°Π·Ρ
ΠΎΠ΄ΠΈ Π·Π° Π·Π΄ΡΠ°Π²Π΅ΠΎΠΏΠ°Π·Π²Π°Π½Π΅. ΠΡΠ²Π΅ΠΆΠ΄Π°Π½Π΅ΡΠΎ Π½Π° Π½ΠΎΠ² Π³Π΅Π½Π΅ΡΠΈΡΠ΅Π½ ΠΏΡΠΎΠ΄ΡΠΊΡ ΠΎΠ±Π°ΡΠ΅ Π±ΠΈ ΠΌΠΎΠ³Π»ΠΎ Π΄Π° Π΄ΠΎΠ²Π΅Π΄Π΅ Π΄ΠΎ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠΈ Ρ ΠΏΡΠΈΠ»Π°Π³Π°Π½Π΅ΡΠΎ ΠΌΡ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ½Π°ΡΠ° ΠΏΡΠ°ΠΊΡΠΈΠΊΠ°. ΠΠΈΠ΅ ΠΈΠ·Π³ΠΎΡΠ²ΠΈΡ
ΠΌΠ΅ ΠΊΠΎΠ½ΡΡΠΎΠ»Π½Π° ΠΊΠ°ΡΡΠ° ΡΡΡ ΡΠΏΠΈΡΡΠΊ Π²ΡΠΏΡΠΎΡΠΈ, Ρ ΠΏΠΎΠΌΠΎΡΡΠ° Π½Π° ΠΊΠΎΡΡΠΎ Π΄Π° ΡΠ΅ ΠΈΠ·ΡΠ»Π΅Π΄Π²Π°Ρ ΡΠ°Π·Π»ΠΈΡΠΈΡΡΠ° ΠΌΠ΅ΠΆΠ΄Ρ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡΠ΅. ΠΠ°ΡΠ°ΡΠ° ΡΠ΅Π» Ρ ΡΠΎΠ·ΠΈ ΡΠΏΠΈΡΡΠΊ Π΅ Π΄Π° ΡΡΡΠ°Π½ΠΎΠ²ΠΈΠΌ ΡΠ²ΠΎΠΉΡΡΠ²Π° Π½Π° Π°Π»ΡΠ΅ΡΠ½Π°ΡΠΈΠ²Π½ΠΈΡΠ΅ Π³Π΅Π½Π΅ΡΠΈΡΠ½ΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π°, ΠΊΠΎΠΈΡΠΎ Π±ΠΈΡ
Π° ΠΌΠΎΠ³Π»ΠΈ Π΄Π° ΡΠ° ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ°ΡΠΈΡΠ½ΠΈ ΠΏΡΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ½Π° ΡΠΏΠΎΡΡΠ΅Π±Π°. ΠΠ°Π²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΠΎ ΠΏΡΠ΅Π΄ΡΠΊΠ°Π·Π²Π°Π½Π΅ Π½Π° Π΅Π²Π΅Π½ΡΡΠ°Π»Π½ΠΈ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠΈ ΠΏΠΎΠ΄ΠΏΠΎΠΌΠ°Π³Π° Π²Π½ΠΈΠΌΠ°ΡΠ΅Π»Π½ΠΈΡ ΠΏΠΎΠ΄Π±ΠΎΡ ΠΈ ΠΎΠ±ΡΡΠ»Π°Π²Ρ Π²ΡΠ²Π΅ΠΆΠ΄Π°Π½Π΅ΡΠΎ Π½Π° ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ΡΡΠΎΡΠΎ Π³Π΅Π½Π΅ΡΠΈΡΠ½ΠΎ Π»Π΅ΠΊΠ°ΡΡΡΠ²ΠΎ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ½Π°ΡΠ° ΠΏΡΠ°ΠΊΡΠΈΠΊΠ°. Π Π½Π°ΡΡΠΎΡΡΠ°ΡΠ° ΡΡΠ°ΡΠΈΡ ΡΠ°Π·Π³Π»Π΅ΠΆΠ΄Π°ΠΌΠ΅ ΡΠ°Π·Π»ΠΈΡΠ½ΠΈΡΠ΅ ΠΏΠΎΠ·ΠΈΡΠΈΠΈ Π² Π½Π°ΡΠ°ΡΠ° ΠΊΠ°ΡΡΠ° ΠΈ ΡΠΏΠΎΠΌΠ΅Π½Π°Π²Π°ΠΌΠ΅ Π·Π° Π½ΡΠΊΠΎΠΈ ΠΎΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠΈΡΠ΅, ΠΊΠΎΠΈΡΠΎ ΡΠΌΠ΅ ΡΡΠ΅ΡΠ°Π»ΠΈ ΠΏΡΠ΅Π· ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΡΠ΅ Π½ΡΠΊΠΎΠ»ΠΊΠΎ Π³ΠΎΠ΄ΠΈΠ½ΠΈ. ΠΡΡΠ²Π°ΠΌΠ΅, ΡΠ΅ Ρ ΠΈΠ·ΠΏΠΎΠ»Π·Π²Π°Π½Π΅ΡΠΎ Π½Π° ΠΊΠΎΠ½ΡΡΠΎΠ»Π½Π°ΡΠ° ΠΊΠ°ΡΡΠ° Π±ΠΎΠ»Π½ΠΈΡΠ½ΠΈΡΠ΅ ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈ ΡΠ΅ ΠΌΠΎΠ³Π°Ρ ΠΏΠΎ-Π΄ΠΎΠ±ΡΠ΅ Π΄Π° ΠΏΡΠ°Π²ΡΡ ΠΎΠΏΡΠΈΠΌΠ°Π»Π½ΠΈΡ ΠΈΠ·Π±ΠΎΡ Π½Π° Π³Π΅Π½Π΅ΡΠΈΡΠ½ΠΎ Π»Π΅ΠΊΠ°ΡΡΡΠ²ΠΎ, ΡΡΠΎΡΠ²Π΅ΡΡΡΠ²Π°ΡΠΎ Π½Π° ΠΊΠΎΠ½ΠΊΡΠ΅ΡΠ½ΠΈΡΠ΅ ΠΈΠ·ΠΈΡΠΊΠ²Π°Π½ΠΈΡ Π½Π° Π΄Π°Π΄Π΅Π½Π° Π±ΠΎΠ»Π½ΠΈΡΠ°.
Therapeutically dosed low molecular weight heparins in renal impairment:a nationwide survey
Purpose International guidelines vary in their recommendations whether or not to reduce the therapeutic dose of low molecular weight heparins (LMWHs) in renal impairment. The use of anti-Xa monitoring as a basis of dose adjustments is also a matter of debate. As this may lead to variations in treatment policies, we aimed to study the treatment policies of therapeutically dosed LMWHs in renal impairment in Dutch hospitals. Methods An 11-item survey was distributed between June 2020 and March 2021 to hospital pharmacists, representing Dutch hospital organisations. Primary outcomes were the dosing regimens of therapeutically dosed LMWHs in renally impaired patients. Secondary outcomes were the proportion of hospitals that used anti-Xa monitoring and the anti-Xa target range used. Results There was a response from 56 of 69 (81%) Dutch hospital organisations where in each case a hospital pharmacist completed the survey. In these hospitals, 77 LMWH regimens were in use. In 76 of 77 (99%) regimens, a regular dose reduction was used at the start of treatment. Fifty-five of these hospitals used a dose reduction if estimated glomerular filtration rate (eGFR) < 50 ml/min and 17 used a dose reduction if eGFR < 30 ml/min. Anti-Xa levels were not routinely monitored in 40% of regimens, while 22% monitored anti-Xa if eGFR < 50 ml/min, 27% if eGFR < 30 ml/min and 10% in other eGFR cutoff values. Target ranges of 1.0-2.0 IU/ml (once daily) and 0.5/0.6-1.0 IU/ml (twice daily) were used in 69% of regimens that included monitoring of anti-Xa. Conclusion Treatment policies show substantial diversity in therapeutically dosed LMWHs in renally impaired patients. The most commonly used treatment regimen was a regular dose reduction if eGFR is < 50 ml/min, without anti-Xa monitoring
ΠΠΎΡΠΎΠ΄Ρ ΠΏΠ΅ΡΡΠ°Π½ΠΈΠΊΠΈ β ΡΠ΅Π΄ΠΊΠΈΠ΅ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ Π²ΡΡΠΎΠΊΠΎΠΉ ΠΊΡΠ΅ΠΏΠΎΡΡΠΈ β ΡΠ½ΠΈΠΊΠ°Π»ΡΠ½ΡΠ΅ ΡΡΠΈΠΊΡΠΈΠΎΠ½Π½ΡΠ΅ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ
Π ΠΎΠ·Π³Π»ΡΠ΄Π°ΡΡΡΡΡ ΠΏΠΈΡΠ°Π½Π½Ρ ΠΏΡΠΈ ΠΏΡΠ΄Π³ΠΎΡΠΎΠ²ΡΡ Π΄ΠΎ Π²ΡΠ΄ΠΏΡΠ°ΡΡΠ²Π°Π½Π½Ρ ΠΏΠΎΠ»ΠΎΠ³ΠΈΡ
Π²ΡΠ³ΡΠ»ΡΠ½ΠΈΡ
ΠΏΠ»Π°ΡΡΡΠ² Π½Π°
Π²Π΅Π»ΠΈΠΊΠΈΡ
Π³Π»ΠΈΠ±ΠΈΠ½Π°Ρ
Π² ΡΠΌΠΎΠ²Π°Ρ
ΡΠ°Ρ
ΡΠΈ Β«ΠΠΎΠ²ΠΆΠ°Π½ΡΡΠΊΠ° ΠΠ°ΠΏΡΡΠ°Π»ΡΠ½Π°Β» Π’ΠΠ "ΠΠ’ΠΠ Π‘Π²Π΅ΡΠ΄Π»ΠΎΠ²Π°Π½ΡΡΠ°ΡΠΈΡ". ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π²ΠΌΡΡΡΡΡΠΈΡ
ΠΏΡΠ΄Π³ΠΎΡΠΎΠ²ΡΡ Π²ΠΈΡΠΎΠ±ΠΊΡ ΠΏΠΎΡΡΠ΄. ΠΠ°ΠΏΡΠΎΠΏΠΎΠ½ΠΎΠ²Π°Π½ΠΎ ΠΌΠΎΠΆΠ»ΠΈΠ²ΠΎΡΡΡ ΠΏΡΠΎΠ΅ΠΊΡΡΠ²Π°Π½Π½Ρ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠ³ΠΎ Π²ΠΈΠ΄ΠΎΠ±ΡΡΠΊΡ ΡΡΠΏΡΡΠ½ΡΡ
ΠΊΠΎΡΠΈΡΠ½ΠΈΡ
ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΡΠ² ΠΏΡΠΈ ΠΏΡΠ΄Π³ΠΎΡΠΎΠ²ΡΡ ΠΠ½ΡΡΠ°ΡΠΈΡΡΠ²ΡΡΠΊΠΎΠ³ΠΎ ΠΏΠ»Π°ΡΡΡΠ² Π΄ΠΎ Π²ΠΈΠ΄ΠΎΠ±ΡΡΠΊΡ.The questions in preparation for mining of shallow coal seams at great depths in the mine
"Dolzhanskaya Capital" LLC "DTEK Sverdlovantratsit." Investigations of host rocks of underground working. Suggested the possibility of designing an integrated co-production of useful components in preparation Antratsitovskogo of flat seam to production
Sex differences associated with adverse drug reactions resulting in hospital admissions
Background Adverse drug events, including adverse drug reactions (ADRs), are responsible for approximately 5% of unplanned hospital admissions: a major health concern. Women are 1.5-1.7 times more likely to develop ADRs. The main objective was to identify sex differences in the types and number of ADRs leading to hospital admission. Methods ADR-related hospital admissions between 2005 and 2017 were identified from the PHARMO Database Network using hospital discharge diagnoses. Patients aged >= 16 years with a drug possibly responsible for the ADR and dispensed within 3 months before admission were included. Age-adjusted odds ratios (OR) with 95% CIs for drug-ADR combinations for women versus men were calculated. Results A total of 18,469 ADR-related hospital admissions involving women (0.35% of all women admitted) and 14,678 admissions involving men (0.35% of all men admitted) were included. Most substantial differences were seen in ADRs due to anticoagulants and diuretics. Anticoagulants showed a lower risk of admission with persistent haematuria (ORadj 0.31; 95%CI 0.21, 0.45) haemoptysis (ORadj 0.47, 95%CI 0.30,0.74) and subdural haemorrhage (ORadj 0.61; 95%CI 0.42,0.88) in women than in men and a higher risk of rectal bleeding in women (ORadj 1.48; 95%CI 1.04,2.11). Also, there was a higher risk of admission in women using thiazide diuretics causing hypokalaemia (ORadj 3.03; 95%CI 1.58, 5.79) and hyponatraemia (ORadj 3.33, 95%CI 2.31, 4.81) than in men. Conclusions There are sex-related differences in the risk of hospital admission in specific drug-ADR combinations. The most substantial differences were due to anticoagulants and diuretics.Peer reviewe
Unintentional guideline deviations in hospitalized patients with two or more antithrombotic agents:an intervention study
Purpose Treatment schedules for antithrombotic therapy are complex, and there is a risk of inappropriate prescribing or continuation of antithrombotic therapy beyond the intended period of time. The primary aim of this study was to determine the frequency of unintentional guideline deviations in hospitalized patients. Secondary aims were to determine whether the frequency of unintentional guideline deviations decreased after intervention by a pharmacist, to determine the acceptance rate of the interventions and to determine the type of interventions. Methods We performed a non-controlled prospective intervention study in three teaching hospitals in the Netherlands. We examined whether hospitalized patients who used the combination of an anticoagulant plus at least one other antithrombotic agent had an unintentional guideline deviation. In these cases, the hospital pharmacist contacted the physician to assess whether this deviation was intentional. If the deviation was unintentional, a recommendation was provided how to adjust the antithrombotic regimen according to guideline recommendations. Results Of the 988 included patients, 407 patients had an unintentional guideline deviation (41.2%). After intervention, this was reduced to 22 patients (2.2%) (p < 0.001). The acceptance rate of the interventions was 96.6%. The most frequently performed interventions were discontinuation of an low molecular weight heparin in combination with a direct oral anticoagulant and discontinuation of an antiplatelet agent when there was no indication for the combination of an antiplatelet agent and an anticoagulant. Conclusion A significant number of hospitalized patients who used an anticoagulant plus one other antithrombotic agent had an unintentional guideline deviation. Intervention by a pharmacist decreased unintentional guideline deviations
Voluntarily reported prescribing, monitoring and medication transfer errors in intensive care units in The Netherlands
Background Medication errors occur frequently in intensive care units (ICU). Voluntarily reported medication errors form an easily available source of information. Objective This study aimed to characterize prescribing, monitoring and medication transfer errors that were voluntarily reported in the ICU, in order to reveal medication safety issues. Setting This retrospective data analysis study included reports of medication errors from eleven Dutch ICU's from January 2016 to December 2017. Method We used data extractions from the incident reporting systems of the participating ICU's. The reports were transferred into one database and categorized into type of error, cause, medication (groups), and patient harm. Descriptive statistics were used to calculate the proportion of medication errors and the distribution of subcategories. Based on the analysis, ICU medication safety issues were revealed. Main outcome measure The main outcome measure was the proportion of prescribing, monitoring and medication transfer error reports. Results Prescribing errors were reported most frequently (nβ=β233, 33%), followed by medication transfer errors (nβ=β85, 12%) and monitoring errors (nβ=β27, 4%). Other findings were: medication transfer errors frequently caused serious harm, especially the omission of home medication involving the central nervous system and proton pump inhibitors; omissions and dosing errors occurred most frequently; protocol problems caused a quarter of the medication errors; and medications needing blood level monitoring (e.g. tacrolimus, vancomycin, heparin and insulin) were frequently involved. Conclusion This analysis of voluntarily reported prescribing, monitoring and medication transfer errors warrants several improvement measures in these processes, which may help to increase medication safety in the ICU
Medication screening using Beers and STOPP/START criteria for elderly patients: Association between potentially inappropriate medication and medication-related hospital admissions
OBJECTIVE To assess the risk of medication-related hospital admissions associated with inappropriate medication use applying the Beers and the STOPP/START criteria. There are multiple screening methods to detect and reduce potentially inappropriate medication [PIM] and prescribing omissions (PPOs). Whether this will result in less medication-related hospitalisations is unknown. DESIGN A nested case-control study was conducted with a subset of patients of the Hospital Admissions Related to Medication (HARM) study. METHODS Cases were defined as patients β₯65 years with a potentially preventable medication-related hospital admission. For each case one control was selected, matched on age and sex. The primary determinant was defined as the presence of one or more PlMs and/or PPOs according to the Beers 2012 and the STOPP/START criteria. The strength of the association between a PIM/PPO and a medication-related hospital admission was evaluated with multivariate logistic regression and expressed as odds ratios with 95% confidence intervals (Cl95). RESULTS PlMs and PPOs detected with the STOPP/START criteria are associated with medication-related hospital admissions [OR 3.47; CI95 1.70-7.09], while for the presence of PIMs according to the Beers 2012 criteria a non-significant trend was visible (ORadj 1.49; CI95 0.90-2.47). CONCLUSION Both the STOPP/START criteria and the Beers 2012 criteria can be used to identify older people at risk for medication-related problems. The choice which set of criteria should be used is more dependent on other factors (e.g. national guidelines, practical considerations) than on the association of each set with ADR-related hospital admission
Geriatric pharmacotherapy : optimisation through integrated approach in the hospital setting
Since older patients are more vulnerable to adverse drug-related events, there is a need to ensure appropriate prescribing in these patients in order to prevent misuse, overuse and underuse of drugs. Different tools and strategies have been developed to reduce inappropriate prescribing; the available measures can be divided into medication assessment tools, and speciο¬c interventions to reduce inappropriate prescribing. Implicit criteria of inappropriate prescribing focus on appropriate dosing, search for drug-drug interactions, and increase adherence. Explicit criteria are consensus-based standards focusing on drugs and diseases and include lists of drugs to avoid in general or lists combining drugs with clinical data. These criteria take into consideration differences between patients, and stand for a medication review, by using a systematic approach. Different types of interventions exist in order to reduce inappropriate prescribing in older patients, such as: educational interventions, computerized decision support systems, pharmacist-based interventions, and geriatric assessment. The effects of these interventions have been studied, sometimes in a multifaceted approach combining different techniques, and all types seem to have positive effects on appropriateness of prescribing. Interdisciplinary teamwork within the integrative pharmaceutical care is important for improving of outcomes and safety of drug therapy. The pharmaceutical care process consists offour steps, which are cyclic for an individual patient. These steps are pharmaceutical anamnesis, medication review, design and follow-up of a pharmaceutical care plan. A standardized approach is necessary for the adequate detection and evaluation of drug-related problems. Furthermore, it is clear that drug therapy should be reviewed in-depth, by having full access to medical records, laboratory values and nursing notes. Although clinical pharmacists perform the pharmaceutical care process to manage the patientβs drug therapy in every day clinical practice, the physician takes the ultimate responsibility for the care of the patient in close collaboration with nurses
- β¦